Skip to main content
Clinical Trials/NCT02330718
NCT02330718
Unknown
N/A

Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia

Yonsei University1 site in 1 country1,500 target enrollmentMay 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Malignant Hematologic Disorder
Sponsor
Yonsei University
Enrollment
1500
Locations
1
Primary Endpoint
the number of patients with malignant hematologic disorders to examine the new prognostic factors and therapeutic targets
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to elucidate the factors which are associated with the diagnosis and predict prognosis and therapeutic targets by collecting specimens of tissue sample, peripheral blood, and bone marrow aspirates at the time of diagnosis or relapse/refractory in patients with malignant hematologic disorders except acute leukemia. This study is eligible for patients who are diagnosed with malignant hematologic disorders except acute leukemia or who will have diagnostic procedure with suspicion of having hematologic malignancy. Prospective cohort is for patients who are not in treatment for hematologic malignancy. Retrospective cohort is for patients who are diagnosed and in treatment.

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
April 2020
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The patients with malignant hematologic disorders except acute leukemia who are diagnosed pathologically according to the revised 2008 WHO classification of tumours of haematopoietic and lymphoid tissue or who will have diagnostic procedure with suspicion of having hematologic malignancy.
  • Any gender and age ≥ 19 years
  • Written informed consent
  • Diagnosed after 2005-01-01 in retrospective cohort group.

Exclusion Criteria

  • Patients who cannot understand or disagree the informed consent
  • Patients who diagnosed with acute leukemia

Outcomes

Primary Outcomes

the number of patients with malignant hematologic disorders to examine the new prognostic factors and therapeutic targets

Time Frame: 5 years

Study Sites (1)

Loading locations...

Similar Trials